Raymond James & Associates Kodiak Sciences Inc. Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.48 $36,630 - $68,900	-7,268 Reduced 39.45%	11,155 $85,000
Q1 2022 May 11, 2022	SELL	$7.09 - $89.45 $31,068 - $391,969	-4,382 Reduced 19.22%	18,423 $142,000
Q4 2021 Feb 08, 2022	SELL	$80.85 - $128.49 $2,829 - $4,497	-35 Reduced 0.15%	22,805 $1.93 Million
Q3 2021 Nov 02, 2021	SELL	$81.97 - $106.94 $153,119 - $199,763	-1,868 Reduced 7.56%	22,840 $2.19 Million
Q2 2021 Aug 11, 2021	SELL	$77.2 - $126.54 $730,003 - $1.2 Million	-9,456 Reduced 27.68%	24,708 $2.3 Million
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $136,405 - $203,120	1,235 Added 3.75%	34,164 $3.87 Million
Q4 2020 Feb 12, 2021	SELL	$60.78 - $154.03 $584,703 - $1.48 Million	-9,620 Reduced 22.61%	32,929 $4.84 Million
Q3 2020 Nov 04, 2020	SELL	$45.05 - $59.27 $25,092 - $33,013	-557 Reduced 1.29%	42,549 $2.52 Million
Q2 2020 Jul 28, 2020	BUY	$42.74 - $66.25 $23,079 - $35,775	540 Added 1.27%	43,106 $2.33 Million
Q1 2020 Apr 21, 2020	SELL	$38.18 - $73.95 $146,343 - $283,450	-3,833 Reduced 8.26%	42,566 $2.03 Million
Q4 2019 Feb 12, 2020	SELL	$13.9 - $76.65 $4,197 - $23,148	-302 Reduced 0.65%	46,399 $3.34 Million
Q3 2019 Nov 07, 2019	BUY	$10.24 - $17.57 $478,218 - $820,536	46,701 New	46,701 $672,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $392M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.